Programs & Partners

It is our ambition that our technology will underpin the development and commercialisation of the next generation of DNA products.

We are therefore working in collaboration with big pharma, leading biotechs and esteemed academics and research institutes, to leverage our dbDNA™ platform in areas of high unmet need where dbDNA™ may offer unique or improved therapies or devices.

Our pipeline

Preclinical
Early clinical
Late clinical

We are working in partnership with Cancer Research UK and the University of Southampton to develop a therapeutic DNA vaccine, TGL-100, for head and neck squamous cell carcinoma (HNSCC).

Cancer vaccines present antigens that prime the immune system, driving it to attack cancer. These therapies have shown significant promise in clinical studies, but use has been limited by slow and expensive manufacturing. Touchlight’s technology will allow for larger scale production, enabling improved availability.

Cancer Research UK’s Centre for Drug Development will sponsor and manage a Phase I/II clinical trial to test TGL-100 in HNSCC patients with recurrent metastatic disease.

Read press release

Our dbDNA™ technology is uniquely suited to enabling rapid, global-scale production of vaccines as a pandemic countermeasure for emerging infectious diseases.

As well as supplying material for other COVID-19 vaccine programs, we are working with a team of vaccine development and infectious and respiratory disease experts to develop a DNA SARS-CoV-2 vaccine.

We aim to develop a vaccine that can be delivered via minimally invasive routes that induce strong mucosal and systemic immunity, and will eliminate the necessity for cold chain in distribution.

Read press release

We have formed a new joint venture company with Stonehaven Incubate AG: Touchlight Aquaculture LLC. Together we will use our dbDNA™ platform to develop new DNA vaccine solutions in the field of aquaculture.</>

DNA vaccines have the potential to enable cost-efficient, safe and more effective immunisation with shorter production timelines, improving availability. They have been shown to be safe and effective with approvals already granted for veterinary use, but widespread adoption has been limited by commercial scalability. Touchlight’s technology will allow for larger scale commercial production at a significantly lower cost.

Read press release

Contact us

We are seeking strategic collaborations

If you’re interested in collaborating or partnering with Touchlight to use our dbDNA™ platform to advance the next generation of DNA products, we’d like to hear from you.

Get in touch